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The goal or the study was to assess if aprotinin, a protease
inhibitor, could be used to antagonize in vivo the effects of
recombinant tissue-type plasminogen activator (rt-PA).
The time coarse of the lysis of a radioactive jugular vein
thrombus was monitored continuously with an external
gamma counter in anesthetized rabbits
. Recombinant (-PA
(0.25 mg) was given intravenously as a bolus injection (10%
of the dose), followed by a 4 h infusion (90% of the dose).
Rabbits received aprotinin 20 min after the start of the
infusion as an intravenous bolus Injection at a dose of
60,000 lU/kg (a
= 4) or 20,000 lU/kg In = 4).
Recombinant tissue-type plasminogen activator (rt-PA) is a
potent thrombolytic drug that is effective in patients with
myocardial infarction (1-4)
.
Its use has been associated with
major bleeding complication rates of 8% (5), 15% (6) and
17% (2). Bleeding complications such as cerebral hemor-
rhage can be life-threatening and with the increasing use of
n-PA, their absolute number will increase .
Until recently, no antidote for ri-PA-induced bleeding
had been described . It was always thought that in case of
hemorrhagic complications . stopping rl-PA administration
was sufficient because the half-life of n-PA is short (7).
However, it has been shown that in vivo the rate of throm-
bolysis is not parallel to the plasma concentration of rt-PA.
Thrombolysis can continue without any measurable rt-PA
concentration in plasma (8) . This is one reason why the use
of a recombinant plasminogen activator inhibitor to antago-
nize the effects of rt-PA was recently proposed (9) . This
specific inhibitor of n-PA reduced the n-PA-induced in-
crease in bleeding time in rabbits
. To our knowledge, the
clinical use of this inhibitor has not been described,
In contrast, aprotinin is a protease inhibitor that has been
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The rate of lysis in the different groups was compared 2,
60 and 180 min after aprinin administration. Both doses
of aprotinin immediately stopped IMomidysis. Thrombd-
ysis was still blocked at 180 ode with the highest dose but
not with the lowest dose. Mot	, sprtinin could pre-
vent the increasein bleeding time secondary to the iniectkw
of rt-PA. These results suggest that apre iia right be 00
in vivo as an antidote for et-PA.
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used in patients with acute pancreatitis, abnormal blood loss
and shock
(10).
In vitro, aprotinin blocks the thrombolylic
effect of plasmin and, in this way, the thrombotytic effects of
plasminogen activators (1 I). However. to our knowledge the
antagonizing effects of aprotinin on rt-PA-induced thrombol-
ysis have not been tested in vivo .
We recently modified a previously described model (8) to
continuously monitor the lysis of ajugular vein thrombus in
anesthetized rabbits (8)
. In the present study, we assessed
the effects of aprotinin during administration of rt-PA in this
model. Moreover, because the bleeding time is a relatively
good predictor of hemorrhagic events secondary to admin-
istration of rt-PA (12). we evaluated the effects of rt-PA on
the prolongation of bleeding time
.
Methods
Thrombolysis experiments .
Burgundy rabbits weighing
2.5 to 3 kg were anesthetized by intravenous injection of
pentobarbital (35 mg/kg body weight) (Vetanarcol, Veteri-
naria AG). Additional pentobarbital was given when needed
to maintain anesthesia
. The rabbit was tracheotontized and
its lungs were ventilated by a mixture of 50% room air and
50% oxygen
. A catheter was introduced into a femoral vein
for infusing drugs and another catheter was implanted into
the femoral artery for blood sampling.
An artificial thrombus was produced
in the jugular vein as
described by Cotten
et al. (12). Briefly, the external jugular
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Figure 1 . Time course of thrombotysis in the four experimental
groups
. Each point represents the mean value ± SEM for all rabbits
in each group. Aprotinin was given 20 min after the bolus injection
of either recombinant tissue-type plasminogen activator (TPA) or
saline solution . i.v. = intravenously
.
vein was exposed through a paramedial incision in the neck
and carefully dissected. Small side branches were ligated
and the facial vein was calnulated . A polyester thread
(Novolene 4 .0, SSC) was introduced into the jugular vein to
maintain the clot in place during lysis. Two clamps were
positioned at the proximal and distal parts of the jugular vein
segment (approximately 4 cm long), which was then. emptied
of all blood by suction through the facial vein catheter.
Indium-125-labeled human fibrinogen (Amersham) contain-
ing approximately 800,000 counts/min was mixed with the
fresh rabbit blood and 10 IU of thrombin (F. Hoffmann-La
Roche) and injected into the jupuiar vein segment through
the facial vein catheter. The clot was aged for 30 min before
both vessel clamps were removed . Then heparin (100 lU/kg)
(Liquemin, F. Hoffmann-La Roche) was given intravenously
to prevent further incorporation if fibrinogen into the clot .
Fifteen minutes after removal of the clamps, administration
of rt-FA was started . Wild-type one-chain rt-PA (Genentech)
was dissolved in 0.3 M of sodium chloride containing 0
.05%
Tween 80 (polysorbate 80)
. Aprotinin (Trasylol, Bayer) was
dissolved in saline solution. These studies conformed to the
Position of the American Heart Association on Research
Animal Use .
Thrombolysis was evaluated by continuously monitoring
the decrease in
thrombus radioactivity as a measure of the
decrease in thrombus size. For this purpose, a gamma
detector (model 8 SHAIMl2, Harsaw) connected to a multi-
channel analyzer (model ND 62, Nuclear Data) was posi-
tioned 2 cm over the jugular vein a few minutes after
introduction of the radioactive clot into the isolated jugular
vein segment
. Radioactivity was continuously recorded with
a counting time of 45 s (Fig. 1) . The decrease in radioactivity
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was displayed on the multichannel analyzer and recorded on
a floppy disk . Stability of the clot was assessed by measuring
the radioactivity for 15 min after release of the clamps .
At the end of the experiments, residual thrombus was
removed and the background radioactivity of the remaining
preparation was measured with the detector in the same
position as during the thrombolysis experiment .
Protocol . Four groups of rabbits were studied . One group
of four rabbits was given only the rt-PA vehicle and was used
as the control group. The three other groups received rt-PA
(0.25 mg/kg) given as a bolus injection (10% of the total dose)
followed by a continuous infusion (v0% of the total dose)
over 4 h . Among these three groups, one received only rt-PA
(n = 6) and the two others received aprotinin (20,000 IU/kg,
n = 4 or 60,000 IU/kg, n = 4) given as a bolus injection 20
min after the start of rt-PA administration . With this design,
it was possible to determine whether the thrombus could be
lysed during the first 20 min of the study . To assess the
effects of aprotinin, we compared the rate of lysis in the
different groups 2, 60 and 180 min after administration of
aprotinin .
To estimate the rate of lysis, curve fitting was done for
each rabbit separately. The counts were adjusted for the
initial and the background radioactivity . Only data measured
after the time of aprotinin administration (20 min) were used.
For rabbits that did not receive aprotinin, a nonlinear
regression model (PROC NLIN, SAS Institute) with an
exponential decrease was used :
T(t) =Ae
-
r+L,
where T is the thrombus size in percent, A is the lysable
fraction, L is the theoretically unlysable fraction, t is time
and y is the lysis rate . For rabbits that received aprotinin, a
cubic polynomial (PROC REG, SAS Institute) was fitted to
the data.
At 2, 60 and 180 min after administraB9n
of
aprotinin, the
lysis rate relative to the remaining thrombus at that time was
calculated from the estimated regression variables . The
effect of the different dosing regimens on the relative lysis
rate was compared using a weighted one-way analysis of
variance (PROC GLM, SAS Institute) with the factor dose
group, Weights were the inverses of the variances of the
relative lysis rate in each group.
Bleeding done experiments. Two groups of rabbits were
anesthetized and ventilated as in the thrombolysis experi-
ments . Template bleeding time was measured by making a
I mm incision in the left ear of the rabbit with a lancet
(Autodisc lancet, Boehringer) . The ear of the rabbit was
maintained on a surface of water kept at 37°C and the end of
bleeding was determined by looking at the blood dropping in
water.
Bleeding time was determined at baseline, 5 and I0 min
after administration of heparin (100 lU/kg) and 5 min after
injection of rt-PA (0.5 mg/kg followed by 0.5
mg/k&
per h).
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Table 1. Effects of Aprotinin on Thrombolysis Induced by n-PA
'p < 0.05 versus control group : tp < 0.01 versus control group
: 30 <
0.001 vemen control group : tp < 0.01 versus recombinant tissue-type plas-
etinegen activator (n-PAl group:
(p
< 0.001 versus n-PA group . Thrombol .
ysis ate was determined after aprotinin injection
.
This high dose of rt-PA was chosen because preliminary
results showed that lower doses of rt-PA did not increase
bleeding time in our experimental model. One group of four
rabbits received only rt-PA and the other group of six was
treated simultaneously with rt-PA and aprotinin (60,000
IU/kg). Both groups were compared by an unpaired I test .
Results
Thrombolysis experiments. In the control group that did
not receive rt-PA, the rate of thrombolysis was very slow
(Fig . 1) . In contrast, administration of rt-PA induced rapid
thrombolysis with an exponential shape . The bolus injection
of aprotinin dramatically slowed thrombolysis in a dose-
dependent fashion . The rate of lysis in the four experimental
groups is given in Table I At 2 min niter administration of
aprotinin, the rate of thrombolysis after both doses of
aprotinin was equal to the rate of thrombolysis observed in
the control group that did not receive rt-PA . At 60 min after
injection of aprotinin, the rate of thrombolysis was still
decreased with both doses. However, at 180 min after
administration of aprotinin, the rate of lysis was decreased
only in the high dose group (60,000 IU/kg of aprotinin).
Bleeding time experiments
. Bleeding time increased ap-
proximately 100% after administration of heparin and by
>100% with rt-PA (Fig . 2) . Aprotinin completely prevented
this increase in bleeding time .
Discussion
beds of aprodeio
on thrombolysis induced by rt-PA .
These results show that in vivo aprotinin can block the
effects of rt-PA
. Moreover
. using an external gamma
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Figure 2 . Effects of aprotinin on the increase in bleeding time due
to recombinant tissue-type plasminogen activator (TPA) . Two
groups of rabbits were treated. After control measurement of
bleeding time, they received heparin and then recombinant tissue-
type plasminogen activator alone In = 4) or in combination with
aprotinin In = 6). "'p < 0.001 versus tbccontrol group treated with
placebo . 5' = 5 min : 10' = 10 min .
coar
r na a
counter. we were able to show that the effect of aprotinin has
a very short onset and is long-lasting .
Aprotinin is a protease inhibitor that inhibits plasmin. Its
clinical indications were recently reviewed (10) . Aprotinin
has beep
. used in patients with acute pancreatitis, blood loss
and shock (10). In vitro, it was shown (11) that aprotinin
could block the effects of rt-PA. Our results confirm that
aprotinin can also be used in vivo .
The onset of action of aprotinin is very short. This was an
interesting point to check because an antidote for rt-PA-
induced bleeding could be useful only if it has a very short
onset of action; rt-PA has a short half-life (approximately 3
min) in rabbits (7). Thus, cessation of the infusion of rt-PA
leads to a rapid decline in its plasma concentration (7) .
However, we recently showed (8) that the time course of the
thrombolysis is not parallel to the time course of the plasma
concentration of rt-PA. Cessation of the rt-PA infusion leads
to a nearly complete arrest of thrombolysis in approximately
1 h
(8).
Thus, the advantage of aprotinin is its immediate
antagonism of rt-PA
.
Another interesting point is that the effect of
aprotinin
was rather long-lasting, allowing its administration as a bolus
dose. However, our results show that the duration of action
of aprotinin is clearly dose dependent . A dose of 60,080
IU/kg is needed to obtain a 3 h duration of action
.
Effects at sprain on the rt-PA-idaced icrease IN
bleeding time. Bleeding time was recently shown (13) to be
correlated with bleeding complications during treatment
of
acute myocardial infarction
. Thus, it was important to show
that aprotinin not only could stop the throenbolytic effect of
rt-PA, but also prevent the increase of bleeding time due to
n-PA . Recently, recombinant plasminogen activator inhibi-
tor I was shown (9) to reverse the bleeding tendency
Experimental
Group No.
Thrombolysis Rate 1%0 of remaining
thrombus/min)
2 Min 60 Min 180 Min
Control 4 0.034
0.033 0.019
0.012 0.006 0.007
n-PA 6 0.9641 0 .592t 0 .669!
0.130 0 .137 0 .167
nt-PA 4 0.076(1 0.190
0.359-
+ aprotinin
(20,000 IMAM 0.012' 0.0435
0.125
rt-PA 4 0.03311 0.06111 0.0935
+ aprotinin
160,0001U/kgl
0
.007 0.006' 0.030'
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associated with the combined administration of rt-PA and
aspirin in rabbits. In that study, tranexamic acid was signif-
icantly less poleri than the rt-PA inhibitor in reversing the
bleeding tendency, but only one dose was used .
Clinical implications.
In the present study, aprotinin
could completely prevent the increase in bleeding time due
to rt-PA : therefore, no improvement in efficacy could be
expected by using the plasminogen activator inhibitor . How-
ever, the main advantage of using this inhibitor is that it is
believed to be speci€tc . ApJVtinin is a nanspecifr series
protease inhibitor ; it inhibits the effects of rt-PA by inhibiting
ptasmin. its main advantage is that in contrast to the
plasminogen activator inhibitor, it has been used in patients
(lUJ . Moreover. the drawbacks due to its nonspecific effects
are not clear
. Thus, further studies should compare the
effects of aprotinin and rt-PA inhibitor in preclinical exper-
iments to determine which is the most suitable compound for
clinical testing .
We shark J . Lobsiger for lypiag the manuscript and Urs Sprecher far the
technical helpand Thomas B . Tseltupp. MD and Paul Hadvary, PhD far their
helpful cameos.
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